EC
ESLA icon

Elequin Capital’s Estrella Immunopharma ESLA Stock Holding History

Elequin Capital’s Portfolio ESLA Stock Details ESLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,400
Closed -$24K – 653
2022
Q3 		$24K Buy
+2,400
New +$24.1K 0.01% 141

Other funds holding ESLA

KIM
Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return
HHGC
Hunting Hill Global Capital New York $129M AUM 17.34% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
SIA
SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return
LCM
Landscape Capital Management Englewood, New Jersey $1.58B AUM 26.88% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
MC
Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Elequin Capital's ESLA Position: Q4 2022 in Review

Elequin Capital sold out of Estrella Immunopharma (ESLA) in Q4 2022, closing a stake of 2,400 shares — an estimated $24K sold.

Elequin Capital first reported a position in ESLA in Q3 2022 and held it in 1 quarter. The position peaked at $24K in Q3 2022. 13 funds tracked by Wall St. Rank hold ESLA as of Q4 2022.

  • Elequin Capital reported no remaining Estrella Immunopharma position as of Q4 2022 after selling out during the quarter.
  • Elequin Capital sold 2,400 Estrella Immunopharma shares in Q4 2022, an estimated $24K.
  • Elequin Capital first reported a position in Estrella Immunopharma in Q3 2022 and held it in 1 quarter.
  • Elequin Capital's Estrella Immunopharma position peaked at $24K in Q3 2022.
  • 13 funds tracked by Wall St. Rank held Estrella Immunopharma as of Q4 2022.

Based on Elequin Capital's 13F filing for Q4 2022, filed 9 Feb 2023.